Merrick, Sophie;
Rush, Hannah L;
Daniels, Susanna;
Fielding, Alison;
Deveson Kell, Sharon;
Pickering, Lisa;
Langley, Ruth E;
... Gilbert, Duncan C; + view all
(2024)
Hit it hard: qualitative patient perspectives on the optimisation of immune checkpoint inhibition.
British Journal of Cancer
10.1038/s41416-024-02756-x.
(In press).
Preview |
Text
s41416-024-02756-x (1).pdf - Other Download (447kB) | Preview |
Abstract
BACKGROUND: Immune checkpoint inhibitors have transformed the treatment landscape of many cancers, including melanoma and renal cell carcinoma (RCC). Randomised trials are evaluating outcomes from reduced ICI treatment schedules with the aim of improving quality of life, tolerability, and cost-effectiveness. This study aims to provide insight into patient and carer’s perspectives of these trials. METHODS: Seven focus groups were conducted with 31 people with stage IV melanoma, RCC, or caregivers for people receiving ICI. Transcripts were analysed using reflexive thematic analysis. RESULTS: Three themes were generated: 1) “Treatment and clinic visits provide reassurance”: reducing hospital visits may not improve quality of life. 2) “Assessment of personal risk versus benefit”: the decision to participate in an ICI optimisation trial is influenced by treatment response, experience of toxicity and perceived logistical benefits based on the individual’s circumstances. 3) “Pre-existing experience and beliefs about how treatment and trials work”, including the belief that more treatment is better, influence views around ICI optimisation trials. CONCLUSION: This study provides insight into recruitment challenges and recommends strategies to enhance recruitment for ongoing ICI optimisation trials. These findings will influence the design of future ICI optimisation trials ensuring they are acceptable to patients.
| Type: | Article |
|---|---|
| Title: | Hit it hard: qualitative patient perspectives on the optimisation of immune checkpoint inhibition |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1038/s41416-024-02756-x |
| Publisher version: | https://doi.org/10.1038/s41416-024-02756-x |
| Language: | English |
| Additional information: | This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology > MRC Clinical Trials Unit at UCL |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/10193637 |
Archive Staff Only
 |
View Item |
